Analysis BioNTech’s First US Cancer Filing Arrives With a Leadership Vacuum and a Pipeline That Investors Can’t Ignore
BioNTech is about to cross a threshold it has never reached before. The Mainz-based biotech is preparing its inaugural application to the US Food and Drug Administration for a cancer...